Inside sources reveal that Indian pharmaceutical generics firm Lupin, along with other U.S. pharma firms, is considering bidding for GlaxoSmithKline’s auctioned mature and generic drugs.
GSK seeks to divest its lineup of mature drugs in an effort to improve its growth profile by getting rid of its off-patent drugs in North America and Western Europe. The drugs are estimated to bring in annual sales of 1 billion pounds and are expected to fetch two to three times the price on the auction block.